News & Updates

The monoclonal antibody tislelizumab continued to show promise as a treatment alternative in certain subgroups of patients with previously treated advanced hepatocellular carcinoma (HCC), according to subgroup analyses of the phase II, single-arm RATIONALE-208 study.

Patients with bladder cancer suffer from high rates of sexual dysfunction, especially those who have undergone radical treatments, a recent study has found.

Treatment with dolutegravir during pregnancy does not appear to pose an excess risk of adverse birth outcomes, according to two studies presented at the 24th International AIDS Conference in Montreal, Canada.

In clinical trials of patients with unresectable metastatic colorectal cancer (mCRC), conversion to resectability (C2R) rarely happens, reveals a study.

The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.

MammaPrint, a signature test that includes 70 genes, appears to accurately identify hormone receptor-positive breast cancer (HR+BC) patients who are at ultra-low risk of distant recurrence, reports a recent study.

People who consume sugar-sweetened beverages, rather than artificially sweetened beverages or natural juices, are at increased risk of developing inflammatory bowel disease, especially Crohn’s disease, as reported in a study.